Centre Asset Management Has Trimmed By $317,900 Its Facebook (FB) Stake; Staar Surgical Company (STAA) Shorts Lowered By 11.39%

Centre Asset Management Llc decreased Facebook (FB) stake by 1.6% reported in 2017Q3 SEC filing. Centre Asset Management Llc sold 1,870 shares as Facebook (FB)’s stock rose 10.88%. The Centre Asset Management Llc holds 115,080 shares with $19.66 million value, down from 116,950 last quarter. Facebook now has $512.76B valuation. The stock decreased 0.82% or $1.46 during the last trading session, reaching $176.46. About 10.26 million shares traded. Facebook, Inc. (NASDAQ:FB) has risen 26.75% since January 1, 2017 and is uptrending. It has outperformed by 10.05% the S&P500.

Staar Surgical Company (NASDAQ:STAA) had a decrease of 11.39% in short interest. STAA’s SI was 1.32M shares in January as released by FINRA. Its down 11.39% from 1.49 million shares previously. With 207,100 avg volume, 6 days are for Staar Surgical Company (NASDAQ:STAA)’s short sellers to cover STAA’s short positions. The SI to Staar Surgical Company’s float is 5.14%. The stock decreased 2.52% or $0.4 during the last trading session, reaching $15.5. About 133,934 shares traded. STAAR Surgical Company (NASDAQ:STAA) has risen 79.17% since January 1, 2017 and is uptrending. It has outperformed by 62.47% the S&P500.

Analysts await Facebook, Inc. (NASDAQ:FB) to report earnings on February, 7. They expect $1.94 earnings per share, up 56.45% or $0.70 from last year’s $1.24 per share. FB’s profit will be $5.64 billion for 22.74 P/E if the $1.94 EPS becomes a reality. After $1.59 actual earnings per share reported by Facebook, Inc. for the previous quarter, Wall Street now forecasts 22.01% EPS growth.

Since August 7, 2017, it had 0 insider purchases, and 38 selling transactions for $950.72 million activity. Shares for $2.83M were sold by Cox Christopher K on Thursday, December 7. Another trade for 117,829 shares valued at $21.25M was sold by Zuckerberg Mark. Schroepfer Michael Todd had sold 38,058 shares worth $6.53M on Tuesday, October 10. $2.75M worth of Facebook, Inc. (NASDAQ:FB) was sold by FISCHER DAVID B. on Thursday, August 24. 750 shares were sold by Stretch Colin, worth $128,910 on Tuesday, August 8. $502.59 million worth of stock was sold by Koum Jan on Tuesday, August 15. Wehner David M. also sold $2.59M worth of Facebook, Inc. (NASDAQ:FB) shares.

Among 53 analysts covering Facebook (NASDAQ:FB), 49 have Buy rating, 2 Sell and 2 Hold. Therefore 92% are positive. Facebook has $235.0 highest and $88 lowest target. $183.47’s average target is 3.97% above currents $176.46 stock price. Facebook had 211 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, November 5 by Stifel Nicolaus. Piper Jaffray maintained Facebook, Inc. (NASDAQ:FB) on Wednesday, October 11 with “Buy” rating. The rating was maintained by Wells Fargo with “Buy” on Wednesday, September 27. The stock of Facebook, Inc. (NASDAQ:FB) has “Buy” rating given on Monday, August 10 by Bank of America. As per Monday, June 5, the company rating was maintained by Jefferies. JP Morgan maintained the shares of FB in report on Thursday, April 28 with “Overweight” rating. The stock of Facebook, Inc. (NASDAQ:FB) has “Buy” rating given on Wednesday, August 30 by Jefferies. Canaccord Genuity maintained Facebook, Inc. (NASDAQ:FB) on Thursday, December 1 with “Buy” rating. Bank of America maintained it with “Buy” rating and $125.0 target in Thursday, November 5 report. The stock of Facebook, Inc. (NASDAQ:FB) has “Buy” rating given on Thursday, July 27 by FBN Securities.

Investors sentiment decreased to 1.15 in 2017 Q3. Its down 0.25, from 1.4 in 2017Q2. It worsened, as 53 investors sold FB shares while 618 reduced holdings. 128 funds opened positions while 644 raised stakes. 1.63 billion shares or 0.88% more from 1.62 billion shares in 2017Q2 were reported. Mackenzie holds 0.11% or 119,735 shares in its portfolio. 22 were accumulated by Alphamark Advsr Limited Liability. Palo Cap owns 8,603 shares for 0.78% of their portfolio. Wealthcare Capital Ltd Liability Corporation reported 456 shares. E&G LP reported 10,855 shares. Private Wealth Advisors has invested 1.4% of its portfolio in Facebook, Inc. (NASDAQ:FB). Diligent Investors Llc holds 0.39% in Facebook, Inc. (NASDAQ:FB) or 3,155 shares. 13,406 are held by First Manhattan Com. Towercrest Capital Management holds 0.69% of its portfolio in Facebook, Inc. (NASDAQ:FB) for 5,275 shares. Condor Cap Mgmt holds 0.91% or 26,603 shares. Fuller Thaler Asset Mngmt, California-based fund reported 37,950 shares. Partner Fund Lp owns 588,286 shares. Coldstream Management Incorporated accumulated 67,115 shares. 235,878 were accumulated by Qs Invsts Ltd Liability. Jarislowsky Fraser holds 1,550 shares.

STAAR Surgical Company, together with its subsidiaries, designs, develops, makes, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company has market cap of $638.05 million. The firm provides Visian implantable collamer lenses to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It currently has negative earnings. It also offers minimally invasive intraocular lenses (IOLs), including foldable IOLs for use in minimally invasive cataract surgical procedures; aspheric IOLs that produce a clearer image than traditional spherical lenses; and nanoFLEX IOL, a single piece collamer aspheric optic, as well as preloaded injectors for use in cataract surgery.

Among 2 analysts covering STAAR Surgical (NASDAQ:STAA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. STAAR Surgical has $21.0 highest and $7 lowest target. $20.50’s average target is 32.26% above currents $15.5 stock price. STAAR Surgical had 11 analyst reports since January 29, 2016 according to SRatingsIntel. Canaccord Genuity maintained STAAR Surgical Company (NASDAQ:STAA) rating on Sunday, October 8. Canaccord Genuity has “Buy” rating and $15.0 target. As per Friday, November 17, the company rating was maintained by Canaccord Genuity. The stock of STAAR Surgical Company (NASDAQ:STAA) earned “Hold” rating by Canaccord Genuity on Monday, July 10. The firm has “Buy” rating given on Monday, September 25 by Canaccord Genuity. The rating was initiated by Benchmark with “Hold” on Friday, January 29. The firm has “Hold” rating given on Thursday, August 3 by Canaccord Genuity. The stock of STAAR Surgical Company (NASDAQ:STAA) has “Hold” rating given on Monday, September 4 by Canaccord Genuity. As per Wednesday, November 8, the company rating was maintained by Canaccord Genuity. Benchmark maintained it with “Buy” rating and $21.0 target in Monday, November 20 report.